[Elsevier] Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study |
|
This post will be closed automatically in 2026-10-23 08:35
Reward10points
|
post
reply
points
20
10
Being nice to stakeholders: The effect of economic policy uncertainty on corporate social responsibility
10
Study on four pyridine-based difluoroboron compounds for mechanofluorochromic behaviors, the ink-free writing and detection of latent fingerprints
10
Beyond Hemodynamics
10
Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study
10
Surgical Site Infections
